|
| Press Releases |
|
 |
|
| Monday, May 18, 2026 |
|
|
エーザイ、「SX 銘柄 2026」に初選定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、経済産業省と東京証券取引所が共同で選定・表彰する「SX 銘柄 2026」に初めて選定されましたので、お知らせします。 more info >> |
|
| Friday, May 8, 2026 |
|
|
エーザイとバイオジェン・インク、抗 Aβ抗体レカネマブの皮下注射製剤「LEQEMBI(R) IQLIK(TM)」の早期アルツハイマー病に対する初期療法に関する米国 FDA による優先審査の状況について |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A.Viehbacher、以下 バイオジェン）は、このたび、米国食品医薬品局（FDA）が、抗 Aβ抗体レカネマブの週 1 回投与の皮下（SC）注射製剤（米国製品名：LEQEMBI IQLIK）について、早期アルツハイマー病（AD）に対する初期療法としての生物製剤承認一部変更申請（sBLA）の審査期間を 3 カ月延長したことをお知らせします。 more info >> |
|
| Wednesday, April 22, 2026 |
|
|
エーザイとMerck & Co., Inc、進行腎細胞がん（RCC）患者様を対象とした一次治療としての併用療法を評価する臨床第III相「LITESPARK-012」試験の状況について |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）と Merck &Co., Inc., Rahway, NJ, USA（北米以外では MSD）は、このたび、進行淡明細胞型腎細胞がん（RCC）患者様の一次治療としての併用療法を評価した臨床第 III 相試験 LITESPARK-012 の結果についてお知らせします。 more info >> |
|
| Tuesday, April 21, 2026 |
|
|
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) |
| Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada), and Eisai (Headquarters: Tokyo, CEO: Haruo Naito) today announced results from the Phase 3 LITESPARK-012 trial evaluating combination treatments for the firstline treatment of patients with advanced clear cell renal cell carcinoma (RCC). more info >> |
|
| Friday, March 27, 2026 |
|
|
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy |
| Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, announced today that an application for LENVIMA(R) (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, has been submitted in Japan for the additional dosage and administration in combination with WELIREG(R) (belzutifan), the first-in-class oral hypoxiainducible factor-2 alpha (HIF-2a) inhibitor from MSD, for the treatment of unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy. more info >> |
|
|
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency |
| Eisai Co., Ltd., a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc., a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). more info >> |
|
| Monday, March 23, 2026 |
|
|
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026 |
| Eisai Co., Ltd. and Biogen Inc. announced today that new real‑world findings from an analysis of long‑term treatment persistence and baseline characteristics among people receiving intravenous (IV) lecanemab (generic name, brand name LEQEMBI?), an anti‑amyloid‑β (Aβ) protofibril antibody, showed that most patients continue with ongoing lecanemab therapy after the initial 18 months of treatment. more info >> |
|
| Thursday, March 19, 2026 |
|
|
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide) |
| Eisai Co., Ltd. announced today that the administration of the anticancer agent EZH2 inhibitor "Tazverik(R) Tablets 200 mg" (generic name: tazemetostat hydrobromide), which is manufactured and marketed in Japan by Eisai should be discontinued. We plan to discontinue sales of this product once we have confirmed that it is no longer being administered to any patients. more info >> |
|
| Tuesday, March 17, 2026 |
|
|
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") has announced the establishment of Eisai Global Capability Centre (EGCC) within Eisai Knowledge Centre, India, in Visakhapatnam (Vizag), Andhra Pradesh, India. more info >> |
|
| Thursday, March 12, 2026 |
|
|
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it is launching an initiative to raise public awareness of the importance of sleep in collaboration with the smartphone application "Pokemon Sleep" more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Sharp to Exhibit at The 3rd SPEXA - Space Business Expo
May 18, 2026 17:34 JST
|
|
|
Your Go-To Travel Checklist for Smarter, Reward-Focused Travel Planning
May 18, 2026 16:32 HKT/SGT
|
|
|
Tabor Redefines Anti-Drone Testing with Software-Defined SDR Platform
May 18, 2026 16:30 HKT/SGT
|
|
|
MHIEC Receives Waste Treatment Technology Verification Report from JESC for Its Fluidized Bed-type Gasification and Reforming System
May 18, 2026 17:17 JST
|
|
|
2026年、日本の音楽サブスク利用意識に変化——料金・通信環境・音質から見る新たな比較基準
May 18, 2026 16:00: JST
|
|
|
MHI Thermal Systems Receives A' Design Awards
-- Recognition at Italy's International Design Competition for the Hydrolution EZY Series of Air-to-Water Heat Pumps and the ZT Series of Residential-Use Air-Conditioners --
May 18, 2026 16:26 JST
|
|
|
エーザイ、「SX 銘柄 2026」に初選定
May 18, 2026 14:50: JST
|
|
|
MHIEC、「流動床式ガス化改質システム」の廃棄物処理技術検証結果書を日本環境衛生センターから取得
May 18, 2026 14:50: JST
|
|
|
Tallgrass and Mitsubishi Power Americas Announce Turbine Allocation for Cheyenne Power Hub
May 18, 2026 15:15 JST
|
|
|
Paying Off Debt but Still Want to Save? Here's How to Manage Both
May 18, 2026 14:00 HKT/SGT
|
|
|
S CUBE Capital Announces Strategic Acquisition by InCred Capital to enhance Global Asset Management Capabilities
May 18, 2026 12:30 HKT/SGT
|
|
|
三菱重工、長崎海運人材育成協会向けCTVのウォータージェット推進装置を受注
May 18, 2026 12:20: JST
|
|
|
三菱重工サーマルシステムズ、伊「A'デザインアワード2026」を受賞
May 18, 2026 12:15: JST
|
|
|
JCB and Wonder Advance Cashless Taxi Payments in Hong Kong
May 18, 2026 10:00 JST
|
|
|
「星樞計劃」正式發布 鈞達股份多家下屬公司成為上海太空算力產業生態夥伴發起及首批單位
May 17, 2026 12:51 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
